Gilead Sciences (GILD) Dividends Paid - Common (2009 - 2026)
Gilead Sciences (GILD) reported Dividends Paid - Common of $1.0 billion for Q1 2026, up 3.59% on a YoY basis from $1.0 billion in Q1 2025, and up 4.63% quarter-over-quarter from $994.0 million in Q4 2025.
Gilead Sciences (GILD) Dividends Paid - Common (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Dividends Paid - Common for 13 years, with the latest figure at $1.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Dividends Paid - Common rose 3.59% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $4.0 billion (up 2.39% YoY), and the FY2025 full-year result was $4.0 billion, up 2.17% from the prior year.
- Dividends Paid - Common for Q1 2026 stood at $1.0 billion, up from $994.0 million in the prior quarter.
- The five-year high for Dividends Paid - Common was $1.0 billion in Q1 2026, with the low at $931.0 million in Q4 2022.
- Historically, Dividends Paid - Common has averaged $969.8 million across 5 years, with a median of $973.0 million in 2024.
- Annual changes were most pronounced in 2022 — Dividends Paid - Common gained 4.14% — and 2024, when it advanced 1.14%.
- Gilead Sciences' Dividends Paid - Common stood at $931.0 million in 2022, then advanced by 1.5% to $945.0 million in 2023, then advanced by 2.96% to $973.0 million in 2024, then climbed by 2.16% to $994.0 million in 2025, then rose by 4.63% to $1.0 billion in 2026.
- The last three Dividends Paid - Common figures came in at $1.0 billion (Q1 2026), $994.0 million (Q4 2025), and $995.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends Paid - Common (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -866.88 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 1.55 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 3.13 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 3.09 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 2.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.36 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.04 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.45 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.28 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.04 Bn |
| Mar 31, 2026 | 1.04 Bn |
| Dec 31, 2025 | 994.00 Mn |
| Dec 31, 2025 | 994.00 Mn |
| Sep 30, 2025 | 995.00 Mn |
| Sep 30, 2025 | 995.00 Mn |
| Jun 30, 2025 | 997.00 Mn |
| Jun 30, 2025 | 997.00 Mn |
| Mar 31, 2025 | 1.00 Bn |
| Mar 31, 2025 | 1.00 Bn |
| Dec 31, 2024 | 973.00 Mn |
| Dec 31, 2024 | 973.00 Mn |
| Sep 30, 2024 | 977.00 Mn |
| Sep 30, 2024 | 977.00 Mn |
| Jun 30, 2024 | 978.00 Mn |
| Jun 30, 2024 | 978.00 Mn |
| Mar 31, 2024 | 980.00 Mn |
| Mar 31, 2024 | 980.00 Mn |
| Dec 31, 2023 | 945.00 Mn |
| Dec 31, 2023 | 945.00 Mn |